Edward A. Sausville

39.7k total citations · 7 hit papers
329 papers, 30.9k citations indexed

About

Edward A. Sausville is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Edward A. Sausville has authored 329 papers receiving a total of 30.9k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Molecular Biology, 149 papers in Oncology and 37 papers in Hematology. Recurrent topics in Edward A. Sausville's work include Cancer-related Molecular Pathways (56 papers), Cancer therapeutics and mechanisms (36 papers) and Cancer Treatment and Pharmacology (27 papers). Edward A. Sausville is often cited by papers focused on Cancer-related Molecular Pathways (56 papers), Cancer therapeutics and mechanisms (36 papers) and Cancer Treatment and Pharmacology (27 papers). Edward A. Sausville collaborates with scholars based in United States, United Kingdom and Ukraine. Edward A. Sausville's co-authors include Adrian M. Senderowicz, Peter J. Worland, Dominic A. Scudiero, Susan Band Horwitz, J. Peisach, James F. Battey, Gurmeet Kaur, Angelika M. Burger, Melinda G. Hollingshead and Janet Dancey and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Edward A. Sausville

328 papers receiving 29.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 1.2k citations Julian Adams, Edward A. Sausville et al. profile →
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

1998 1.1k citations Edward A. Sausville, Dominic A. Scudiero et al. profile →
A gene expression database for the molecular pharmacology of cancer

2000 1.1k citations Timothy G. Myers, Dominic A. Scudiero et al. profile →
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

1997 760 citations Timothy G. Myers, Dominic A. Scudiero et al. profile →
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.

1994 699 citations M Bubb, Adrian M. Senderowicz et al. Journal of Biological Chemistry profile →
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

2001 621 citations Daniel Zaharevitz, Edward A. Sausville et al. profile →
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer

1985 543 citations Marion M. Nau, James F. Battey et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward A. Sausville United States	92	19.3k	11.7k	3.4k	3.0k	2.8k	329	30.9k
Scott H. Kaufmann United States	95	25.8k 1.3×	11.9k 1.0×	3.7k 1.1×	2.8k 0.9×	1.8k 0.6×	406	36.2k
Neal Rosen United States	100	24.7k 1.3×	12.2k 1.0×	4.2k 1.3×	2.4k 0.8×	5.7k 2.0×	255	34.8k
Takashi Tsuruo Japan	89	16.6k 0.9×	12.4k 1.1×	2.8k 0.8×	2.1k 0.7×	1.2k 0.4×	446	27.7k
Ting‐Chao Chou United States	60	14.1k 0.7×	8.1k 0.7×	2.2k 0.7×	1.4k 0.5×	2.3k 0.8×	350	29.3k
Nathanael S. Gray United States	104	30.5k 1.6×	10.9k 0.9×	3.0k 0.9×	4.0k 1.3×	4.9k 1.7×	476	42.2k
James A. McCubrey United States	79	16.1k 0.8×	6.8k 0.6×	3.9k 1.1×	1.6k 0.5×	1.9k 0.7×	421	24.9k
Kevan M. Shokat United States	96	24.3k 1.3×	6.9k 0.6×	2.4k 0.7×	5.4k 1.8×	2.4k 0.8×	305	34.2k
Charles Dumontet France	69	9.2k 0.5×	8.6k 0.7×	1.9k 0.6×	1.6k 0.5×	2.2k 0.8×	377	20.7k
Michael M. Gottesman United States	101	27.8k 1.4×	32.9k 2.8×	4.3k 1.3×	2.5k 0.8×	2.2k 0.8×	408	53.6k
Paul Workman United Kingdom	85	18.6k 1.0×	5.8k 0.5×	4.4k 1.3×	2.3k 0.8×	2.4k 0.8×	535	27.7k

Countries citing papers authored by Edward A. Sausville

Since Specialization

Citations

This map shows the geographic impact of Edward A. Sausville's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward A. Sausville with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward A. Sausville more than expected).

Fields of papers citing papers by Edward A. Sausville

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward A. Sausville. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward A. Sausville. The network helps show where Edward A. Sausville may publish in the future.

Co-authorship network of co-authors of Edward A. Sausville

This figure shows the co-authorship network connecting the top 25 collaborators of Edward A. Sausville. A scholar is included among the top collaborators of Edward A. Sausville based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward A. Sausville. Edward A. Sausville is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ng, Vincent Y., Jennifer L. Fogel, Michael E. Kallen, et al.. (2024). Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PD-L1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities. Cureus. 16(10). e72119–e72119. 1 indexed citations

Schwartz, Gary K., Mark A. Dickson, Patricia LoRusso, et al.. (2016). Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity. Cancer Science. 107(4). 499–506. 17 indexed citations

Trikalinos, Nikolaos A., Young Kwok, Olga Goloubeva, Minesh P. Mehta, & Edward A. Sausville. (2016). Socioeconomic status and survival in glioblastoma. 9(2). 4131–4136. 3 indexed citations

Heredia, Alonso, Nhut Le, Ronald B. Gartenhaus, et al.. (2015). Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proceedings of the National Academy of Sciences. 112(30). 9412–9417. 79 indexed citations

Sausville, Edward A., et al.. (2015). Cytotoxic drugs: past, present and future. Cancer Chemotherapy and Pharmacology. 77(1). 1–1. 11 indexed citations

LoRusso, Patricia, Karthik Venkatakrishnan, E. Gabriela Chiorean, et al.. (2013). Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Investigational New Drugs. 32(1). 160–170. 13 indexed citations

Naumann, R. Wendel, Robert L. Coleman, Robert A. Burger, et al.. (2013). PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology. 31(35). 4400–4406. 169 indexed citations

Gojo, Ivana, Alexander E. Perl, Selina M. Luger, et al.. (2013). Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Investigational New Drugs. 31(5). 1217–1227. 42 indexed citations

Shiozawa, Ken, Takeo Nakanishi, Ming Tan, et al.. (2009). Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias. Clinical Cancer Research. 15(5). 1698–1707. 54 indexed citations

10.

Shelton, Phillip M., Edward A. Sausville, Takeo Nakanishi, et al.. (2007). Breast cancer cells resistant to anti-hormone treatments retain sensitivity to Aminoflavone (NSC 686288). Molecular Cancer Therapeutics. 6. 3 indexed citations

11.

Kolonin, Mikhail G., Laura Bover, Jessica D. Sun, et al.. (2006). Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries. Cancer Research. 66(1). 34–40. 63 indexed citations

12.

Stone, Erica L., Michele Vítolo, Kurt Bachman, et al.. (2006). Response of breast cancer cell lines to aminoflavone (NSC 686288) is associated with histone H2AX phosphorylation and estrogen receptor expression. Cancer Research. 66. 132–132. 4 indexed citations

13.

Amornphimoltham, Panomwat, Vyomesh Patel, Akrit Sodhi, et al.. (2005). Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck. Cancer Research. 65(21). 9953–9961. 189 indexed citations

14.

Waes, Carter Van, Angela A. Chang, Peter F. Lebowitz, et al.. (2005). Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology*Biology*Physics. 63(5). 1400–1412. 93 indexed citations

15.

McGrath, Connor F., Nagarajan Pattabiraman, Glen E. Kellogg, et al.. (2005). Homology Model of the CDK1/cyclin B Complex. Journal of Biomolecular Structure and Dynamics. 22(5). 493–502. 35 indexed citations

16.

Sausville, Edward A.. (2002). Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends in Molecular Medicine. 8(4). S32–S37. 130 indexed citations

17.

Kitada, Shinichi, Maryla Krajewska, Xianhui Zhang, et al.. (1998). Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines.. Europe PMC (PubMed Central). 152(1). 51–61. 96 indexed citations

18.

Bubb, M, et al.. (1994). 細胞毒性天然産物,ジャスプラキノリドはアクチン重合を誘導し,ファロイジンのF-アクチンヘの結合をきっ抗的に阻害する. Journal of Biological Chemistry. 269(21). 14869–14871. 4 indexed citations

19.

Viallet, Jean, Yoav Sharoni, Harold Frucht, et al.. (1990). Cholera toxin inhibits signal transduction by several mitogens and the in vitro growth of human small-cell lung cancer.. Journal of Clinical Investigation. 86(6). 1904–1912. 28 indexed citations

20.

Krystal, Geoffrey W., Michael J. Birrer, James M. Way, et al.. (1988). Multiple Mechanisms for Transcriptional Regulation of the myc Gene Family in Small-Cell Lung Cancer. Molecular and Cellular Biology. 8(8). 3373–3381. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact